mericitabine
Mericitabine (RG-7128) is an antiviral drug, a deoxycytidine analog. It was developed as a treatment for hepatitis C, acting as a NS5B RNA polymerase inhibitor, but while it showed a good safety profile in clinical trials, it was not sufficiently effective to be used as a stand-alone agent. However mericitabine has been shown to boost the efficacy of other antiviral drugs when used alongside them, and as most modern treatment regimens for hepatitis C use a combination therapy of several antiviral drugs, clinical trials have continued to see if it can form a part of a clinically useful drug treatment program. — Wikipedia
Clinical trial activity
14 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Feb 1, 2001 (NCT00869661)
Timeline
Indications
Mechanism of action
- RNA-directed RNA polymeraseINHIBITOR
RNA-directed RNA polymerase inhibitor
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
Chemistry & pharmacology
SMILES
CC(C)C(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@](C)(F)[C@@H]1OC(=O)C(C)C- Mol. weight
- 399.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMericitabine ↗
- ChEMBLCHEMBL562967 ↗
Also known as
- 2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine
- mericitabine
- mericitabine
- mericitabine
- mericitabine
- mericitabine
- r7128
- rg7128
- rg 7128
- rg-7128
- ro5024048
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01579019 | Phase 2 | Jul 1, 2012 | Roche |
| NCT01628094 | Phase 2 | Jun 1, 2012 | Roche |
| NCT01483742 | Phase 2 | Apr 1, 2012 | Roche |
| NCT01482390 | Phase 2 | Nov 30, 2011 | Roche |
| NCT01482403 | Phase 2 | Nov 1, 2011 | Roche |
| NCT01331850 | Phase 2 | May 1, 2011 | Roche |
| NCT01278134 | Phase 2 | Feb 1, 2011 | Roche |
| NCT01152671 | Phase 1 | Jun 1, 2010 | Roche |
| NCT01099904 | Phase 1 | Mar 1, 2010 | Roche |
| NCT01057667 | Phase 2 | Feb 1, 2010 | Roche |
| NCT00801255 | Phase 1 | Nov 1, 2008 | Roche |
| NCT00382798 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2006 | Pharmasset, Roche |
| NCT00377182 | Phase 2 | Sep 1, 2006 | Roche |
| NCT00869661 | Phase 2 | Feb 1, 2001 | Roche |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 14 | 13 | 2 | 2001 |
| Pharmasset | For profit | 1 | 1 | 1 | 2006 |